Articles
-
1 month ago |
endpts.com | Reynald Castaneda
GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential pharma-specific tariffs. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
1 month ago |
endpts.com | Reynald Castaneda
Roche and Sanofi said on Thursday morning they have been running scenarios on how US and other tariffs could potentially impact their respective businesses. However …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
Jan 30, 2025 |
endpts.com | Reynald Castaneda
Sanofi is likely to increase its M&A this year since it has more cash in its pockets, as the French pharma also monitors China as …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
Nov 20, 2024 |
endpts.com | Reynald Castaneda
Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
Sep 15, 2024 |
endpts.com | Reynald Castaneda
BARCELONA — In a result that’s likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- Tweets
- DMs Open
RT @RLCscienceboss: #CRISPR isn’t living up to its potential. Thousands of rare diseases that could be treated with gene editing remain unt…
RT @ZacharyBrennan: Prasad, a frequent critic of FDA and vaccine policies, will lead CBER at an interesting time https://t.co/hGeVwfnt1v
RT @ZacharyBrennan: More FDA staff w/decades of experience leave via early retirements, following broad firings from April 1 - https://t.c…